Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-10-21 03:08 CEST (UTC+2h)

BA BE Study with a reference not market authorised [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-10-10 17:09  - Posting: # 17884
Views: 304

Hi Rick,

» I have a new formulation (NF) of a product (P) that has been demonstrated to be BE to a reference Marketed (RM) product, but it is not authorised. And I want to demonstrate BE of my new formulation (NF) vs the product (P) already BE to the Market authorised (RF).

This is a regular type II variation or a line extension depending on whether P stays on the market after you introduce NF.
If you are not the MA holder for P then the situation is not in any way straightforward. At the end of the day the reference should be an article 8 approved product and judging from your question P might not be?!??. Let us hear some more details, please. Ideally name the RF product :-):-)

Can you elaborate on the passage "(...) it is not authorised": What does "it" refer to, is it P, NF or RM?

I could be wrong, but…

Best regards,

- since June 2017 having an affair with the bootstrap.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,396 Posts in 3,726 Threads, 1,074 registered users;
26 users online (0 registered, 26 guests).

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

BEBAC Ing. Helmut Schütz